Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.42 |
| ▸ | GIPR | P48546 | 3/20 | 0.40 |
| ▸ | GLP1R | P43220 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091506 | 0.74 | GCGR (0.50) | GCGRGIPRGLP1RCA1CA2 | |
| SCHEMBL6755519 | 0.72 | GCGR (0.55) | GCGRGIPRGLP1R | |
| SCHEMBL2663036 | 0.72 | GCGR (0.53) | GCGRGIPRGLP1RCA1CA2 | |
| SCHEMBL6750367 | 0.70 | GCGR (0.75) | GCGRGIPRGLP1R | |
| SCHEMBL2660760 | 0.70 | GCGR (0.72) | GCGRGIPRGLP1R | |
| SCHEMBL2663033 | 0.70 | GCGR (0.72) | GCGRGIPRGLP1R | |
| SCHEMBL2663251 | 0.70 | GCGR (0.49) | GCGRGIPRGLP1RCA1CA2 | |
| SCHEMBL9072784 | 0.70 | CA9 (0.64) | GCGRCA1CA2CA7CA9 | |
| SCHEMBL4098930 | 0.69 | GCGR (0.48) | GCGRGIPRGLP1RCA1CA2 | |
| SCHEMBL13799875 | 0.68 | GCGR (0.58) | GCGRGIPRGLP1RPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.